The Scientist

» geron

Most Recent

image: Geron hESC Trial to Resume?

Geron hESC Trial to Resume?

By | May 27, 2014

Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.

0 Comments

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.

0 Comments

image: Geron Sells Stem Cell Assets

Geron Sells Stem Cell Assets

By | January 8, 2013

BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.

0 Comments

image: BioTime Seeks Geron Stem Cell Assets

BioTime Seeks Geron Stem Cell Assets

By | November 13, 2012

Two former Geron CEOs make a bid for the company’s defunct human embryonic stem cell business.

1 Comment

image: First hESC Trial Kaput

First hESC Trial Kaput

By | November 15, 2011

Geron is terminating a clinical trial testing a human embryonic stem cell treatment for spinal cord injury.

30 Comments

Popular Now

  1. First In Vivo Function Found for Animal Circular RNA
  2. Your Body Is Teeming with Weed Receptors
    Features Your Body Is Teeming with Weed Receptors

    And the same endocannabinoid system that translates marijuana's buzz-inducing compounds into a high plays crucial roles in health and disease outside the brain.

  3. Opinion: We Need a Replacement for Beall’s List
  4. Doctors’ Advice to Finish Antibiotics Overlooks Resistance
AAAS